IO Biotech Inc

IO Biotech’s Tumor‑Suppression Tech Faces 87% Stock Drop — What It Means for Investors

IO Biotech’s T‑win platform promises a new immunotherapy for cancer, but its Nasdaq shares plunged 87%—what’s behind the drop and the next steps for investors?

13/02/2026, 23:31

2 minutes to read

IO Biotech’s T-Win Technology: A New Frontier in Cancer Therapy

IO Biotech, a clinical-stage biopharmaceutical company, is revolutionizing cancer therapy with its innovative T-win technology platform, which empowers the immune system to target and disrupt multiple pathways that regulate tumor-induced immunosuppr…

11/08/2025, 12:24

3 minutes to read

IO Biotech Inc. Pioneers Immune-Modulating Cancer Therapies with T-win Technology

IO Biotech is a clinical-stage biopharmaceutical company advancing novel immune-modulating cancer therapies through its proprietary T-win technology platform.

28/07/2025, 19:26

2 minutes to read

IO Biotech Inc. Pioneers Immune-Modulating Cancer Therapies with T-Win Technology

IO Biotech Inc. is a clinical-stage biopharmaceutical company pioneering innovative cancer therapies through its proprietary T-win technology platform.

23/05/2025, 01:30

2 minutes to read